CCND1 and breast carcinoma: Conversely, miR-17-92 family was found to be deleted in approximately 20% of ovarian, breast cancers and melanomas [38], and it was expressed at higher levels in non-metastatic MCF-7 compared with metastatic MDA-MB-231 cells, along with an inhibition of cellular invasion and tumor metastasis through cyclin D1 repression [39].